SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announces that, as envisaged in the Company’s Admission Document dated 29 March 2017, it has agreed an eight month extension to its research contract with the University of Manchester to June 2018. This contract extension includes provision for the appointment of a second technician to the Company. This will increase the Company’s ability to develop its SkinBiotix® platform.
Furthermore, the Company announces that it has recently demonstrated activity of SkinBiotix® at a range of doses in human skin models, and also completed the design of two human safety trials. If successful, these trials will allow the technology to be labelled ‘dermatologically tested’ for its cosmetic application.
Dr. Catherine O’Neill, CEO of SkinBioTherapeutics Plc, said: “We are making progress in our research, and the extension and expansion of our contract with the University of Manchester will allow meaningful progression across the Company. We are pleased with the progress of SkinBiotix, and are confident that it remains on track.
“As a team, we have nurtured relationships with industry stakeholders for many years. Since our IPO, we have continued to ensure potential commercial partners are aware of the capabilities of the SkinBiotix platform.”
